Cost-effectiveness analysis of voice rehabilitation for patients with laryngeal cancer: a randomized controlled study.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 20 12 2019
accepted: 13 02 2020
pubmed: 23 2 2020
medline: 20 11 2020
entrez: 21 2 2020
Statut: ppublish

Résumé

Voice problems are common following radiotherapy for laryngeal cancer. Few studies exist covering the effect of voice rehabilitation, and no previous studies exist regarding the cost of said rehabilitation. This randomized controlled study aimed to analyze the cost-effectiveness of voice rehabilitation after radiotherapy for patients with laryngeal cancer. A total of 66 patients with laryngeal cancer with follow-up data 12 months post-radiotherapy were included. Patients were randomized into receiving either voice rehabilitation (n = 32) or no voice rehabilitation (n = 34). The patient outcome was measured as quality-adjusted life years (QALYs). The index range between 0 and 1, where 0 equals death and 1 represents perfect health. The QALYs were assessed with the European Organization for Research and Treatment of Cancer questionnaire QLQ-C30 mapped to EuroQoL 5 Dimension values. The cost of rehabilitation and other healthcare visits was derived from hospital systems. The patients reported the total amount of sick leave days during the first 12 months following radiotherapy. The cost-effectiveness of the voice rehabilitation was compared with no rehabilitation intervention based on the incremental cost-effectiveness ratio. The cost per gained QALY with voice rehabilitation compared to no rehabilitation from a societal perspective was - 27,594 € (SEK - 250,852) which indicates that the voice rehabilitation is a cost-saving alternative compared to no rehabilitation due to lower costs and a slightly better health outcome. From a healthcare perspective, the voice rehabilitation indicates a cost 60,800 € (SEK 552,725) per gained QALY. From a societal perspective, i.e., including the costs of production loss, voice rehabilitation compared to no voice rehabilitation following radiotherapy for laryngeal cancer seems to be cost-saving. When analyzing only the healthcare costs in relation to health outcomes, voice rehabilitation indicates an incremental cost of 60,800 € per gained QALY, which is just above the threshold of the maximum willingness to pay level.

Identifiants

pubmed: 32078058
doi: 10.1007/s00520-020-05362-8
pii: 10.1007/s00520-020-05362-8
pmc: PMC7547033
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

5203-5211

Références

Br J Cancer. 2001 Jan;84(2):149-56
pubmed: 11161369
J Voice. 2012 May;26(3):381-9
pubmed: 21840171
Acta Oncol. 2004;43(3):284-9
pubmed: 15244253
Radiother Oncol. 2009 Dec;93(3):524-9
pubmed: 19846231
Cancer. 2006 Jan 1;106(1):95-105
pubmed: 16323175
Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1071-8
pubmed: 10421541
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1333-43
pubmed: 12873678
Arch Otolaryngol Head Neck Surg. 2000 Sep;126(9):1097-100
pubmed: 10979123
Health Qual Life Outcomes. 2012 Dec 17;10:151
pubmed: 23244763
Acta Oncol. 1994;33(8):879-85
pubmed: 7818919
Laryngoscope. 2012 Jul;122(7):1589-94
pubmed: 22549455
Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):157-63
pubmed: 10037282
Head Neck. 2008 Jul;30(7):868-74
pubmed: 18302270
Support Care Cancer. 2017 Sep;25(9):2683-2690
pubmed: 28365896
Acta Otolaryngol Suppl. 1969;263:128-9
pubmed: 5269024
Logoped Phoniatr Vocol. 2017 Dec;42(4):167-177
pubmed: 27841694
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):964-972
pubmed: 25035200
Value Health. 2009 Nov-Dec;12(8):1151-7
pubmed: 19558372
Acta Oncol. 1999;38(5):573-80
pubmed: 10427945
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Voice. 2012 May;26(3):398-401
pubmed: 21840168
BMC Cancer. 2008 Mar 27;8:80
pubmed: 18371189
Qual Life Res. 2012 Sep;21(7):1193-203
pubmed: 22012023
Acta Oncol. 2015 Jul;54(7):1017-24
pubmed: 25615892
J Chronic Dis. 1974 Sep;27(7-8):387-404
pubmed: 4436428
Head Neck Oncol. 2011 Apr 19;3:19
pubmed: 21504618
Qual Life Res. 2016 Apr;25(4):891-911
pubmed: 26391884
Biometrics. 1975 Mar;31(1):103-15
pubmed: 1100130
Laryngoscope. 2000 Apr;110(4):593-602
pubmed: 10764003
Head Neck. 2008 May;30(5):600-10
pubmed: 18098302
Value Health. 2009 Jan-Feb;12(1):167-71
pubmed: 18637140
Health Qual Life Outcomes. 2014 Mar 11;12:35
pubmed: 24618388
Laryngoscope. 2016 Sep;126(9):2029-35
pubmed: 27010512
Clin Radiol. 1988 May;39(3):295-6
pubmed: 3396281
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Radiother Oncol. 2009 Feb;90(2):177-82
pubmed: 18937990
J Voice. 2014 Jan;28(1):62-8
pubmed: 23769005

Auteurs

Mia Johansson (M)

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the Gothenburg University, Gothenburg, Sweden.
Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.

Caterina Finizia (C)

Department of Otorhinolaryngology, Head and Neck surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Otorhinolaryngology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.

Josefine Persson (J)

Health Economics and Policy, School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

Lisa Tuomi (L)

Department of Otorhinolaryngology, Head and Neck surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. lisa.tuomi@gu.se.
Department of Otorhinolaryngology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden. lisa.tuomi@gu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH